Stage IV Squamous Cell Lung Carcinoma AJCC v7 Recruiting Phase 2 Trials for Tremelimumab (DB11771)

IndicationStatusPhase
DBCOND0092102 (Stage IV Squamous Cell Lung Carcinoma AJCC v7)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03373760Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerTreatment